Roche is expanding its indications in cancer immunotherapy. Following FDA approvals of its PD-L1 checkpoint inhibitor atezolizumab in NSCLC and bladder cancer patients refractive to platinum-based chemotherapy, the Swiss pharma major is awaiting a FDA decision on whether the antibody is suitable as first-line treatment in a further subpopulation of bladder cancer patients.
Constitutive activation of the mechano-sensor and transcription factor Yes-associated protein (YAP) is key to metastasis and epithelial-mesenchymal transition of triple-negative breast cancer, researchers from the Institute of Cancer Research, London, report.
https://european-biotechnology.com/wp-content/uploads/2024/04/2017_1-6_Metastasis-Switch.jpg9241920Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2017-01-06 09:47:172017-01-06 09:47:17UK researchers find metastasis switch in breast cancer cells
Malte Peters will leave Sandoz to take over as Chief Development Officer of Morphosys AG. Peters succeeds Arndt Schottelius, who held the position for eight yeara.
https://european-biotechnology.com/wp-content/uploads/2024/04/malte-peters.jpg473420h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2017-01-05 15:17:212017-01-05 15:17:21Morphosys: Driving development
/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2017-01-05 10:30:152017-01-05 10:30:15NeRRe Therapeutics pushes leads by €26m Series B financing
Novozymes company Albumedix A/S has appointed Giles Campion new Chief Medical Officer. Campion will be in charge of leading the development efforts of the Danish leader in albumin-based drug delivery.
https://european-biotechnology.com/wp-content/uploads/2024/04/giles-campion.jpg706628h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2017-01-05 09:43:202017-01-05 09:43:20Albumedix: Medical expertise
Milan-based Newron Pharmaceuticals has named Dennis Dionne Vice President Commercial Affairs. Previously, Dionne was Executive Director for Commercial Operations. He replaces Anders Haegerstrand.
The Innovative Medicines Initiative is pushing clinical development of a novel compound against Gram-negative bugs that cause urinary tract and intra-abdominal infections. Backed by IMI, Aicuris is launching a clinical programme for an antibiotic.
The London-based immunotherapy specialist Tiziana Life Sciences bagged the license for the human anti-interleukin 6 receptor antagonist NI-1201 from Swiss Novimmune.
French Sanofi is set to become a global market leader in the non-prescription market by acquiring Boehringer Ingelheim’s consumer healthcare (CHC) business in exchange for Sanofi’s animal health arm Merial.
Deborah Waterhouse, currently Senior Vice President Primary Care, GSK US Pharmaceuticals, will take over as CEO of Viiv Healthcare. She succeeds Dominique Limet, who will step down from the post at the end of March 2017.
https://european-biotechnology.com/wp-content/uploads/2024/04/deborah-waterhouse.jpg473420h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2016-12-28 14:57:002016-12-28 14:57:00Viiv Healthcare: New at the helm
Roche gets FDA priority review for atezolizumab
Latest NewsRoche is expanding its indications in cancer immunotherapy. Following FDA approvals of its PD-L1 checkpoint inhibitor atezolizumab in NSCLC and bladder cancer patients refractive to platinum-based chemotherapy, the Swiss pharma major is awaiting a FDA decision on whether the antibody is suitable as first-line treatment in a further subpopulation of bladder cancer patients.
UK researchers find metastasis switch in breast cancer cells
Latest NewsConstitutive activation of the mechano-sensor and transcription factor Yes-associated protein (YAP) is key to metastasis and epithelial-mesenchymal transition of triple-negative breast cancer, researchers from the Institute of Cancer Research, London, report.
Morphosys: Driving development
AppointmentsMalte Peters will leave Sandoz to take over as Chief Development Officer of Morphosys AG. Peters succeeds Arndt Schottelius, who held the position for eight yeara.
NeRRe Therapeutics pushes leads by €26m Series B financing
Latest NewsNeuronal hypersensitivity specialist NeRRe Therapeutics has closed an oversubscribed Series B financing round led by Fountain Healthcare Partners.
Albumedix: Medical expertise
AppointmentsNovozymes company Albumedix A/S has appointed Giles Campion new Chief Medical Officer. Campion will be in charge of leading the development efforts of the Danish leader in albumin-based drug delivery.
Newron Pharmaceuticals: Commercial head
AppointmentsMilan-based Newron Pharmaceuticals has named Dennis Dionne Vice President Commercial Affairs. Previously, Dionne was Executive Director for Commercial Operations. He replaces Anders Haegerstrand.
Bayer antibiotics spin-out Aicuris bags IMI grant
Latest NewsThe Innovative Medicines Initiative is pushing clinical development of a novel compound against Gram-negative bugs that cause urinary tract and intra-abdominal infections. Backed by IMI, Aicuris is launching a clinical programme for an antibiotic.
Tiziana joins rheumatoid arthritis race
Latest NewsThe London-based immunotherapy specialist Tiziana Life Sciences bagged the license for the human anti-interleukin 6 receptor antagonist NI-1201 from Swiss Novimmune.
Sanofi and Boehringer Ingelheim close ?business swap
Latest NewsFrench Sanofi is set to become a global market leader in the non-prescription market by acquiring Boehringer Ingelheim’s consumer healthcare (CHC) business in exchange for Sanofi’s animal health arm Merial.
Viiv Healthcare: New at the helm
Appointments